Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

aminolevulinic acid intravenous formulation SONALA-001

An intravenous formulation of aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX (PpIX), with potential antineoplastic activity upon magnetic resonance-guided focused ultrasound (MRgFUS). Upon intravenous administration of SONALA-001, ALA readily crosses the blood brain barrier (BBB) and accumulates intracellularly, where ALA is metabolized to the photosensitizer PpIX by enzymes in the heme biosynthesis pathway. Due to the distinct activity of these enzymes in tumor cells, there is a higher accumulation of PpIX in tumor cells. Upon MRgFUS, the energy of ultrasound produces light (sonoluminescence) within the brain and activates PpIX in tumor cells. Ultrasound-activated PpIX catalyzes molecular oxygen to singlet oxygen, an intracellular toxin, which can further react to form superoxide and hydroxyl radicals. This leads to cellular cytotoxic effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ALA intravenous formulation SONALA-001
Code name:SONALA 001
SONALA-001
SONALA001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search